Skip to main
LVTX
LVTX logo

LVTX Stock Forecast & Price Target

LVTX Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

LAVA Therapeutics NV is actively advancing its immuno-oncology pipeline, with a focus on bispecific antibody development using the Gammabody platform, which positions the company to potentially address significant unmet needs in cancer treatment. The recent agreement with XOMA Royalty for an acquisition at a cash price between $1.16 and $1.24 per share reinforces the company's financial stability and strategic growth direction. Additionally, the presence of multiple promising pipeline products such as LAVA-1266 and LAVA-1427 suggests a robust potential for future value creation, indicating a positive long-term outlook for the company's stock.

Bears say

LAVA Therapeutics is facing a negative outlook due to the decision to discontinue its Phase 1 study of LAVA-1266, which suggests significant setbacks in its clinical development pipeline. Additionally, the company's recent acquisition activities have led to a reduction in the price target from $1.50 to $1.24 per share, indicating a reassessment of its financial position and future prospects. The overall shift in strategy and project wind-down may contribute to investor concerns regarding the viability of its remaining pipeline candidates.

LVTX has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LAVA Therapeutics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LAVA Therapeutics NV (LVTX) Forecast

Analysts have given LVTX a Hold based on their latest research and market trends.

According to 4 analysts, LVTX has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LAVA Therapeutics NV (LVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.